Higher LRRFIP1 expression in glioblastoma multiforme is associated with better response to teniposide, a type II topoisomerase inhibitor

Biochemical and Biophysical Research Communications

Volumn 446, Issue 4, 2014, Pages 1261-1267

  Li, Wei Qing ^a   Yu, Hong Yu ^a   Li, Yi Ming ^a   Wang, Xiang ^a   He, Jin ^a   Yan, Hong Zhu ^a   Yang, Dao Hua ^a   Wu, Xiao Jun ^a   Hou, Li Jun ^a   Liu, Hui Min ^a   Xia, Chun Yan ^a   Lu, Yi Cheng ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Glioblastoma multiforme; LRRFIP1; Teniposide; VM 26

Indexed keywords

GLIOBLASTOMA MULTIFORME; LRRFIP1; TENIPOSIDE; VM-26;

ANIMALS; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; MICRORNAS; PROGNOSIS; RNA-BINDING PROTEINS; TENIPOSIDE; TOPOISOMERASE II INHIBITORS; TRANSFECTION; UP-REGULATION;

EID: 84899473553     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.03.105     Document Type: Article

References (26)

1. P.Y. Wen, and S. Kesari Malignant gliomas in adults N. Engl. J. Med. 359 2008 492 507
2. F.B. Furnari, T. Fenton, R.M. Bachoo, A. Mukasa, J.M. Stommel, A. Stegh, W.C. Hahn, K.L. Ligon, D.N. Louis, C. Brennan, L. Chin, R.A. DePinho, and W.K. Cavenee Malignant astrocytic glioma: genetics, biology, and paths to treatment Genes Dev. 21 2007 2683 2710
3. T. Tanaka, Y. Manome, P. Wen, D.W. Kufe, and H.A. Fine Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth Nat. Med. 3 1997 437 442
4. L.A. Stewart Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials Lancet 359 2002 1011 1018
5. W.P. Mason, and J.G. Cairncross Drug insight: temozolomide as a treatment for malignant glioma - impact of a recent trial Nat. Clin. Pract. Neurol. 1 2005 88 95
6. E.G. Van Meir, C.G. Hadjipanayis, A.D. Norden, H.K. Shu, P.Y. Wen, and J.J. Olson Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma CA Cancer J. Clin. 60 2010 166 193
7. G. Jin, S. Cook, B. Cui, W.C. Chen, S.T. Keir, P. Killela, C. Di, C.A. Payne, S.G. Gregory, R. McLendon, D.D. Bigner, and H. Yan HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea Neuro. Oncol. 12 2010 956 966
8. B. Cui, S.P. Johnson, N. Bullock, F. Ali-Osman, D.D. Bigner, and H.S. Friedman Bifunctional DNA alkylator 1,3-bis(2-chloroethyl)-1-nitrosourea activates the ATR-Chk1 pathway independently of the mismatch repair pathway Mol. Pharmacol. 75 2009 1356 1363
9. D.W. Parsons, S. Jones, X. Zhang, J.C. Lin, R.J. Leary, P. Angenendt, P. Mankoo, H. Carter, I.M. Siu, G.L. Gallia, A. Olivi, R. McLendon, B.A. Rasheed, S. Keir, T. Nikolskaya, Y. Nikolsky, D.A. Busam, H. Tekleab, L.A. Diaz Jr., J. Hartigan, D.R. Smith, R.L. Strausberg, S.K. Marie, S.M. Shinjo, H. Yan, G.J. Riggins, D.D. Bigner, R. Karchin, N. Papadopoulos, G. Parmigiani, B. Vogelstein, V.E. Velculescu, and K.W. Kinzler An integrated genomic analysis of human glioblastoma multiforme Science 321 2008 1807 1812
10. H. Yan, D.W. Parsons, G. Jin, R. McLendon, B.A. Rasheed, W. Yuan, I. Kos, I. Batinic-Haberle, S. Jones, G.J. Riggins, H. Friedman, A. Friedman, D. Reardon, J. Herndon, K.W. Kinzler, V.E. Velculescu, B. Vogelstein, and D.D. Bigner IDH1 and IDH2 mutations in gliomas N. Engl. J. Med. 360 2009 765 773
11. S.A. Rao, V. Santosh, and K. Somasundaram Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma Mod. Pathol. 23 2010 1404 1417
12. L. Shi, J. Chen, J. Yang, T. Pan, S. Zhang, and Z. Wang MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity Brain Res. 1352 2010 255 264
13. X. Zhou, J. Zhang, Q. Jia, Y. Ren, Y. Wang, L. Shi, N. Liu, G. Wang, P. Pu, Y. You, and C. Kang Reduction of miR-21 induces glioma cell apoptosis via activating caspase 9 and 3 Oncol. Rep. 24 2010 195 201
14. Y. Li, W. Li, Y. Yang, Y. Lu, C. He, G. Hu, H. Liu, J. Chen, J. He, and H. Yu MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme Brain Res. 1286 2009 13 18
15. M. Weller, B. Muller, R. Koch, M. Bamberg, and P. Krauseneck Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma J. Clin. Oncol. 21 2003 3276 3284
16. P. Yang, H. An, X. Liu, M. Wen, Y. Zheng, Y. Rui, and X. Cao The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a beta-catenin-dependent pathway Nat. Immunol. 11 2010 487 494
17. A. Bagashev, M.C. Fitzgerald, D.F. Larosa, P.P. Rose, S. Cherry, A.C. Johnson, and K.E. Sullivan Leucine-rich repeat (in Flightless I) interacting protein-1 regulates a rapid type I interferon response J. Interferon Cytokine Res. 30 2010 843 852
18. B.P. Lewis, C.B. Burge, and D.P. Bartel Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets Cell 120 2005 15 20
19. T. Papagiannakopoulos, A. Shapiro, and K.S. Kosik MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells Cancer Res. 68 2008 8164 8172
20. S.A. Wilson, E.C. Brown, A.J. Kingsman, and S.M. Kingsman TRIP: a novel double stranded RNA binding protein which interacts with the leucine rich repeat of flightless I Nucleic Acids Res. 26 1998 3460 3467
21. S.Y. Lee, S.Y. Lee, and Y. Choi TRAF-interacting protein (TRIP): a novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-kappaB activation J. Exp. Med. 185 1997 1275 1285
22. C.Y. Wang, D.C. Guttridge, M.W. Mayo, and A.S. Baldwin Jr. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis Mol. Cell. Biol. 19 1999 5923 5929
23. C. Nakanishi, and M. Toi Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs Nat. Rev. Cancer 5 2005 297 309
24. A.E. Pegg Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents Cancer Res. 50 1990 6119 6129
25. J.A. Quinn, S.X. Jiang, D.A. Reardon, A. Desjardins, J.J. Vredenburgh, S. Gururangan, J.H. Sampson, R.E. McLendon, J.E. Herndon 2nd, and H.S. Friedman Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma Cancer 115 2009 2964 2970
26. J.A. Quinn, S.X. Jiang, D.A. Reardon, A. Desjardins, J.J. Vredenburgh, J.N. Rich, S. Gururangan, A.H. Friedman, D.D. Bigner, J.H. Sampson, R.E. McLendon, J.E. Herndon 2nd, A. Walker, and H.S. Friedman Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma J. Clin. Oncol. 27 2009 1262 1267